328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
Sara M. Tolaney(Dana-Farber Cancer Institute), Romualdo Barroso‐Sousa(Hospital Sírio-Libanês), Z. Jiang(Chinese PLA General Hospital), Y.H. Park(Samsung Medical Center), Mothaffar F. Rimawi(Baylor College of Medicine), C. Saura Manich(Vall d'Hebron Hospital Universitari), Andreas Schneeweiß(National Center for Tumor Diseases), Masakazu Toi(Kyoto University), Tinghui Yu(AstraZeneca (United States)), Jagdish Shetty(AstraZeneca (United States)), Pia Herbolsheimer(AstraZeneca (United States)), Sibylle Loibl(Cardiovascular Center Bethanien)
Cited by 27
Abstract
Related Papers
No related papers found
Powered by citation graph analysis